Krystal Biotech, Inc. $KRYS Shares Sold by Aberdeen Group plc

Aberdeen Group plc lessened its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 45.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 59,372 shares of the company’s stock after selling 49,146 shares during the period. Aberdeen Group plc owned about 0.20% of Krystal Biotech worth $10,481,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of KRYS. Hantz Financial Services Inc. grew its position in shares of Krystal Biotech by 8,950.0% in the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock valued at $25,000 after purchasing an additional 179 shares during the period. Bessemer Group Inc. boosted its stake in Krystal Biotech by 106.9% in the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after buying an additional 77 shares during the last quarter. AdvisorNet Financial Inc purchased a new stake in Krystal Biotech in the 3rd quarter valued at about $30,000. Salomon & Ludwin LLC acquired a new position in shares of Krystal Biotech during the 3rd quarter valued at about $33,000. Finally, First Horizon Advisors Inc. increased its stake in shares of Krystal Biotech by 212.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock valued at $34,000 after acquiring an additional 166 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $262.67 on Friday. The company has a market capitalization of $7.68 billion, a PE ratio of 38.35 and a beta of 0.49. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $298.30. The business has a fifty day moving average price of $265.16 and a two-hundred day moving average price of $208.78.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. The company had revenue of $107.11 million during the quarter, compared to analysts’ expectations of $105.30 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%. Sell-side analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on KRYS. TD Cowen reissued a “buy” rating on shares of Krystal Biotech in a research report on Friday, January 9th. Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Jefferies Financial Group upped their price objective on Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a report on Tuesday. Zacks Research cut Krystal Biotech from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Finally, HC Wainwright reissued a “buy” rating and set a $310.00 price target (up previously from $240.00) on shares of Krystal Biotech in a research report on Friday, January 9th. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Krystal Biotech currently has an average rating of “Moderate Buy” and an average target price of $318.75.

Insider Buying and Selling

In related news, CAO Kathryn Romano sold 12,500 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the transaction, the chief accounting officer owned 19,318 shares of the company’s stock, valued at approximately $5,257,200.52. This trade represents a 39.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the transaction, the insider owned 1,413,711 shares in the company, valued at approximately $311,242,613.76. This represents a 1.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 13.70% of the company’s stock.

Key Headlines Impacting Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Q4 earnings beat consensus and management highlighted Vyjuvek sales growth and pipeline progress — Vyjuvek sales rose (~17% cited by coverage) and the company reported expanding U.S. reimbursements (660+), supporting revenue and margin outlooks. Read More.
• Positive Sentiment: Analysts are lifting targets and maintaining Buy views — Chardan raised its price target to $323 (Buy) and HC Wainwright keeps a Buy with a $310 target and quarterly EPS estimates, signaling continued analyst confidence. Read More. and Read More.
• Positive Sentiment: Pipeline expansion: KB707 and RMAT designation narrative gaining attention — coverage highlights KB707’s role in an oncology story and broader HSV‑1 platform opportunities, which supports longer‑term upside. Read More.
• Neutral Sentiment: Analysts and media are re‑rating the story after new data and target resets — several pieces reassess valuation and strategy after the one‑year rally; useful for investors reassessing risk/reward. Read More.
• Neutral Sentiment: Q4 earnings call transcript and coverage available for deeper read — transcript and analyst notes give more detail on international launches (Italy H2 2026) and margin targets (90–95%). Read More.
• Neutral Sentiment: Short‑interest data shows no meaningful days‑to‑cover signal in the most recent snapshot — not a driver of today’s move. (Report entry: short interest flagged as zero.)
• Negative Sentiment: Stock pulled back despite earnings beat — several outlets note intraday selling and a slip after the print, consistent with profit‑taking following the stock’s strong run and some mixed readthroughs on revenue/margins. Read More.
• Negative Sentiment: Market reaction may reflect short‑term rotation and valuation scrutiny after a one‑year rally to new highs — investors may be locking gains even as fundamental metrics remain supportive. Read More.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.